Satclizumab (Anshiping) latest medical insurance price in 2024

Satralizumab (Satralizumab, trade name Enspryng, is a humanized monoclonal antibody drug used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. Satclizumab modulates inflammation by inhibiting the interleukin-6 (IL-6) receptor, a key mediator of the immune response. Satclizumab was approved for medical use in the United States in August 2020 and in the European Union in June 2021.

In mostNMOSD patients, the disease is caused by the production of anti-AQP4 antibodies. Aquaporin 4 is very important for the normal function of nerve cells. The active substance in satralizumab is a monoclonal antibody, a protein designed to block the effects of interleukin-6 (IL-6), a protein involved in the production of anti-AQP4 antibodies in the body. By blocking IL-6, the drug reduces the production of anti-AQP4 antibodies, thus ensuring AQP4 activity. This should prevent nerve cell damage and reduce the symptoms of NMOSD.

The patented drug Saterizumab has been launched in China, sold under the brand name of Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is The price of each box of 120mg (1ml) may be more than 10,000 yuan, which is still relatively expensive. Due to different reimbursement ratios in different regions, the price after reimbursement may be different. Please consult the local medical insurance bureau and other places for details. The price of each box of Satclizumab's original drug sold overseas is more than 10,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.